Navigation Links
Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
Date:5/14/2009

embarked on a major research program to develop innovative cancer drugs. Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim is committed to discovering and developing novel cancer treatments. This commitment is underpinned by using advances in science to develop a range of targeted therapies in areas of medical need, including various solid tumors and hematological cancers.

The current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition. BIBW 2992 entered Phase IIb/III clinical development in NSCLC earlier in 2008 and was granted Fast Track designation for a third/fourth line treatment indication in NSCLC by the US Food & Drug Administration. In addition, the LUME-Lung Phase III clinical trial program, which is investigating BIBF 1120 in combination with standard second-line chemotherapy treatments for patients with advanced NSCLC, is ongoing. In the area of cell-cycle kinase inhibition, Boehringer Ingelheim is developing inhibitors of polo-like kinase 1 (Plk1), a protein that is involved in the processes of cell division. These molecules are in the early stages of clinical development.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of $17 billion (11.6 billion euro) while spending one-fifth of net sales in its largest business segment, Prescription Medicines, on re
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
10. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Company, Inc. (NYSE: LCI ) today announced that ... Annual Growth Conference on Wednesday, August 12, 2015, at ... A webcast of the presentation will be ... visit the web site at least 10 minutes prior ... and install any necessary software.  The presentation will be ...
(Date:7/30/2015)... -- Flexpoint Ford, a private equity firm focused on ... it has entered into a partnership with Alan ... Kastle Therapeutics, LLC (Kastle).  The new company, headquartered in ... developing and commercializing pharmaceuticals targeted toward diseases with high ... already approved for marketing, as well as clinical assets ...
(Date:7/30/2015)... 30, 2015   HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are ... announced total revenue of $73.6 million for the ... million for the quarter ended June 30, 2014. ... million, or nine percentage points, during the three ...
Breaking Medicine Technology:Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 2HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 3HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 4HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 5HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 6HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 7HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 8HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 9HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 10HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 11HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 12HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 13HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 14
(Date:7/30/2015)... , ... July 30, 2015 , ... ... has worked to protect victims in San Diego, California’s Gaslamp Quarter Plaza for ... by Gaslamp Quarter Plaza actively monitor the area for any suspicious activity. These ...
(Date:7/30/2015)... , ... July 30, 2015 , ... Google recently announced ... upcoming dedicated web site. As discussed in a June 8, 2015 article published by ... reported so far have been caused by its computer-driven cars, which such industry players ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... throughout Orange, Riverside, Los Angeles, and San Bernardino counties, today announced that Dr. ... Palliative Care Administrator. Dr. Demoratz is a strong proponent of early access to ...
(Date:7/30/2015)... ... ... The need for accessibility is never greater than when we find ourselves ... as visiting friends and family during these critical moments, hospitals around the Pennsylvania region ... by ChargeItSpot , a Philadelphia-based startup that recently secured a $4M Series A ...
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... ... Florida’s (UCF) College of Medicine as Assistant Professor of Plastic Surgery. This is ... Dr. Clevens has worked closely with the university, developing a strong presence and a ...
Breaking Medicine News(10 mins):Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3
... a move much appreciated, the US Consumer Product Safety Commission ... under the name BABYBJ'RN? Feeding Spoons. , The company ... move was taken in response to consumer feedback regarding the ... use, the tips of the spoon were observed to soften ...
... a new technique to rapidly detect and precisely ... treatments usually required. ,The technique, called desorption ... create a new class of fast, accurate detectors ... security, said R. Graham Cooks, the Henry Bohn ...
... as he checked himself into a treatment centre near his ... Elena Fondacaro, his manager: "Verne was in rehab and now ... illness that comes and goes ... and Verne realised he ... he's determined to maintain his sobriety." ,In ...
... going cross-eyed even though his optician has reassured him that he ... taking up wearing sunglasses to have his eyes covered all the ... But I can see it when I look in the mirror ... said I should put then on so that people don't have ...
... pressure may seem like something that only adults get, ... children can develop it too -- and just as ... risks to children's hearts, brains and lives. ... pressure, surgery is the best option for those with ...
... may be another reason for pregnant and nursing women to ... vegetables like broccoli and cabbage// – it could help protect ... life. ,A new study by scientists from ... laboratory mice, found that supplements of a key phytochemical found ...
Cached Medicine News:Health News:New Technique to Identify Bacteria for Food Safety 2Health News:New Technique to Identify Bacteria for Food Safety 3Health News:Surgery, the Best Option for Kids With High Blood Pressure 2Health News:Surgery, the Best Option for Kids With High Blood Pressure 3Health News:Mother’s Diet During Pregnancy Could Prevent Cancer in Childre 2Health News:Mother’s Diet During Pregnancy Could Prevent Cancer in Childre 3
... and best value in high performance electronic ... ultra lightweight design reduce hand fatigue and ... lever tip ejector , Color coding for ... or for greater performance use Hamilton AdvanTip ...
... The Finnpipette BioControl multichannel ... features as the single ... handle fits allseven multichannel ... tip cone modules. Both ...
... Pipette is ideal for all liquid handling ... ergonomically-placed operating buttons, and various dispensing techniques ... diluting make this a lab favorite. It ... manual pipette without any adverse effects on ...
... for Unparalleled Comfort Pick one of our ... Notice the trigger and ejector positionsright where they ... pipettors are ergonomically designed to help avoid repetitive ... Productivity In The Palm Of Your Hand ...
Medicine Products: